Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence
Open Access
- 28 August 2021
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1353
Abstract
Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has a high affinity towards pro-survival BCL-2 family proteins (i.e., BCL-XL, BCL-2, BCL-W) to induce cell apoptosis effectively. A single navitoclax action potently ameliorates several tumor progressions, including blood and bone marrow cancer, as well as small cell lung carcinoma. Not only that, but navitoclax alone also therapeutically affects fibrotic disease. Nevertheless, outcomes from the clinical trial of a single navitoclax agent in patients with advanced and relapsed small cell lung cancer demonstrated a limited anti-cancer activity. This brings accumulating evidence of navitoclax to be used concomitantly with other chemotherapeutic agents in several solid and non-solid tumors that are therapeutically benefiting from navitoclax treatment in preclinical studies. Initially, we justify the anti-cancer role of navitoclax in combination therapy. Then, we evaluate the current evidence of navitoclax in combination with the chemotherapeutic agents comprehensively to indicate the primary regulator of this combination strategy in order to produce a therapeutic effect.Keywords
Funding Information
- Ministry of Higher Education, Malaysia (FRGS/1/2019/SKK06/UKM/02/7)
This publication has 83 references indexed in Scilit:
- Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemiaBlood, 2013
- Anti-cancer drug discovery and developmentCommunicative & Integrative Biology, 2012
- Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cellsCancer Research, 2012
- PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk StratificationJournal of Clinical Oncology, 2012
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xLCancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Apoptosis and oncogenesis: give and take in the BCL-2 familyCurrent Opinion in Genetics & Development, 2011
- (−)-Gossypol Inhibits Growth and Promotes Apoptosis of Human Head and Neck Squamous Cell Carcinoma In VivoNeoplasia, 2006
- The Hallmarks of CancerCell, 2000